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Sinary We have investigated the effects on breast cancer cell growth of 4-hydroxytamoxifen (4OHT), a
conventional antioestrogen with agonist activity, and 7m-[9-(4,4,5,5,5-pentafluoropentyhlulphinyl)nonylloestra-
1,3,5,(10)-triene-3,17-diol (IC] 182780), a novel, pure antiocstrogen, using established human breast cancer
cell lines and cancer cells obtained directly from breast cancer patients with malignant pleural effusions who
had relapsed on tamoxifen. The effects of the two agents were assessed using the Courtenay-Mills clonogenic
assay, which measures the growth of single cancer cells as colonies suspended in soft agar. The standard assay
was modified by the use of defined serum- and phenol red-free growth medium. The growth of oestrogen
receptor (ER)-positive MCF-7 cells in the assay was oestrogen responsive. Both antioestrogens inhibited the
stimulatory effects of I nrm oestradiol, but ICI 182780 caused significantly greater inhibition than 40HT at
0.1 -1.0jom concentrations. In the absence of oestradiol, 40HT but not ICI 182780 caused significant
stimulation of colony formation at low (0.01-1.00 nM) concentrations. Neither antioestrogen had any effects
on colony formation by the ER-negative Hs578T cell line. Successful colony formation was obtained in
primary cultures from six out of eight malignant effusions. Colony formation was significantly stimulated by
0.1 nm oestradiol in four cases and by 10 nm 40HT in two cases. In contrast, ICI 182780 exhibited no intrinsic
stimulatory activity and significantly inhibited both oestradiol- and 40HT-stimulated cell growth. We conclude
that the agonist activity of 40HT and other conventional antioestrogens may cause treatment failure in some
patients by stimulating breast cancer cell growth. The new, pure antioestrogen ICI 182780 is a more potent
oestrogen antagonist than 4OHT and exhibits no growth-stimulatory activity. This agent may therefore offer
therapeutic advantages over conventional antioestrogens in patients with advanced breast cancer and may be
effective after conventional agents have failed.
Tamoxifen is currently the first-line endocrine treatment of
choice for hormone-responsive breast cancer. Although at
least one-third of patients with advanced breast cancer
initially respond to tamoxifen, almost all eventually relapse
while on continuing treatment. The mechanisms underlying
these treatment failures remain incompletely understood.
While tumour progression to an endocrine-independent
phenotype may explain some treatment failures, it is clear
from the reported response rates to second-line endocrine
therapy (Henderson, 1991) that a significant proportion of
breast tumours remain hormone responsive after tamoxifen
has failed.
Clinical evidence from studies demonstrating tumour re-
sponses to withdrawal of tamoxifen at the time of treatment
failure (Canney et al., 1987; Howell et al., 1992) suggests that
some patients relapse on tamoxifen because their tumours
become stimulated by the agonist (oestrogenic) activity
exhibited by tamoxifen and other non-steroidal anti-
oestrogens.
These clinical findings are supported by the results of
laboratory studies with established human breast cancer cell
lines, showing stimulation of cell growth by tamoxifen both
in vitro (Darbre et al. 1984; Reddel & Sutherland, 1984;
Katzenellenbogen et al., 1987; Wakeling et al., 1989) and in
vivo (Gottardis & Jordan, 1988). However, the relevance of
these experimental studies to human breast cancer may be
diminished by alterations in endocrine responsiveness that
immortalised breast cancer cell lines may undergo during
long-term cultivation (Simon et al., 1984a). As a conse-
quence, established cancer cell lines may become progres-
sively less representative of the cell population of the tumour
from which they originated.
We considered that a more representative experimental
model with which to examine the contribution of tamoxifen's
oestrogenic activity to treatment failure might be achieved by
establishing primary cultures of tumour cells taken directly
from breast cancer patients at the time of relapse on tamoxi-
fen. This would permit the effects of tamoxifen to be
evaluated directly in breast cancer cells from tumours which
appeared clinically to be tamoxifen resistant and compared
with the effects of ICI 182780, a new steroidal antioestrogen,
which appears to be a pure oestrogen antagonist with no
demonstrable agonist activity (Wakeling et al., 1991).
Unfortunately, obtaining tumour cells directly from
patients with advanced breast cancer is frequently impractical
because many patients relapse at sites which are not readily
amenable to surgical biopsy. A previous study by Simon et
al. (1984b) demonstrated that primary monolayer cultures
could be established successfully by using tumour cells
obtained from malignant pleural effusions in patients with
advanced breast cancer who had relapsed in lung or pleura.
Using this technique, Simon et al. (1984b) were able to
demonstrate stimulation of tumour cell proliferation by
tamoxifen in cultures from four out of ten patients.
Because it may prove difficult to prevent the overgrowth of
normal fibroblasts and mesothelial cells using monolayer tis-
sue culture methods, we investigated the relative effects of the
two antioestrogens using the Courtenay-Mills clonogenic
assay (Courtenay & Mills, 1978), which permits the growth
of human cancer cells as colonies suspended in semi-solid
culture medium without excessive growth of normal cell con-
taminants. For the purposes of the present study, the stan-
dard protocol of the Courtenay-Mills assay was modified by
the use of serum-free growth medium, in order to optimise
the culture conditions for demonstrating breast cancer cell
responsiveness to oestrogens and antioestrogens.
The aims of the present study were firstly to characterise
the growth of human breast cancer cells in the Courtenay-
Mills assay under serum-free conditions, using established
cell lines, and secondly to utilise the assay to investigate the
effects of tamoxifen and ICI 182780 in primary cultures of
breast cancer cells taken from patients with advanced breast
cancer who had relapsed on tamoxifen.
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Materal an mthods
Breast cancer cell lines
Oestrogen receptor (ER)-positive MCF-7 cells and ER-
negative Hs578T cells were obtained from the European
Collection of Animal Cell Cultures (ECACC, Porton Down,
UK). Stock monolayer cultures of both cell lines were main-
tained in serum-containing growth medium (SCM), which
comprised Dulbecco's modified Eagle medium (DMEM)
(Gibco, UK) supplemented with 10% fetal calf serum (FCS)
and l0 ignml-' insulin. Cultures were incubated in Falcon
T75 flasks (Falcon, UK) at 37TC in a humidified atmosphere
of 5% carbon dioxide in air. Cells were subcultured at inter-
vals of 4-5 days by resuspension using 0.05% tryp-
sin-0.02% EDTA (Gibco).
Prior to plating out in the Courtenay-Mills assay,
logarithmically growing cells from subconfluent cultures were
harvested by brief trypsinisation using 0.05% trypsin-0.02%
EDTA. The cells were washed twice and resuspended in
defined serum-free growth medium (SFM) (Table I). Single-
cell suspensions were obtained by gentle aspiration through
21 G hypodermic needles and filtration through sterile 35;m
nylon mesh (Nybolt).
Preparation ofcancer cellsfrom patients with malignant
pleural effusions
Metastatic breast cancer cells were obtained from eight
patients who relapsed with malignant pleural effusions while
on tamoxifen. Samples ofpleural effusion fluid were obtained
by needle aspiration under aseptic conditions. Approximately
1,000-1,200 ml of pleural fluid was obtained from each-
patient. After collection of the fluid, preservative-free heparin
was immediately added to give a concentration of
10umml'.
The pleural aspirates were diluted 1:1 with Ham's F12
nutrient mix (F12) (Gibco, UK) to reduce viscosity and
centrifuged at 800 g for 10min. The supernatants were dis-
carded and the cell pellets were resuspended in F12 and
recentrifuged over cushions of lymphocyte preparation fluid
(Lymphoprep; Nyegaard, Oslo, Norway) for 30 min at 400g
in order to remove contaminating erythrocytes. Tumour cells
were collected from the interphase between the Lymphoprep
cushion and the supernatant and were resuspended in freez-
ing medium, which comprised SCM supplemented with 10%
dimethylsulphoxide (Sigma, UK). The resulting cell suspen-
sions were slow-frozen overnight in the vapour phase of
liquid nitrogen and then stored in liquid nitrogen until
required for culture in the Courtenay-Mills assay.
On the day of plating out in the Courtenay-Mills assay,
the frozen tumour cells were thawed rapidly by immersion in
a water bath at 37C. The cells were washed twice and
resuspended in defined SFM. A single-cell suspension was
obtained by gentle aspiration through a 21 G hypodermic
needle and filtration through sterile 35um nylon mesh.
Endocrine reagents
17P-Oestradiol was obtained from Sigma, UK. The anti-
oestrogens, 4-hydroxytamoxifen (40HT) and ICI 182780
were kindly provided by Zeneca (formerly ICI) Pharmaceu-
ticals, UK. We selected 4OHT for use in these studies
because its binding affinity for the ER is higher than that of
tamoxifen and is nearer to the binding affinities of oestradiol
and ICI 182780.
Stock solutions of the antioestrogens and 17-estradiol at
1,000 times the final working concentrations were made up in
absolute ethanol (Analar) and stored at - 20°C.
The Courtenav-Mills clonogenic assay
To set up the assay, 1 ml aliquots of breast cancer cell
suspension at ten times the final cell density required were
mixed with 1 ml aliquots of a solution of August rat erythro-
cytes diluted 1:8 with defined SFM. Appropriate endocrine
Table I Defined serum-free growth medium used in the present
study
DMEM:Ham's F12 1:1
Amphotericin 2 ILgml1
Gentamicin 25jugml-'
Bovine serum albumin fraction V (Sigma) 10mgml'
Epidermal growth factor lOngml-
Insulin 10 ugml-'
Hydrocortisone 0.5 jigml-'
Transferrin 2.5 lAg ml
Glutamine 2 mm
Prostaglandin F2 (Sigma) 0.1 Ilgml-'
L-Thyroxline (Sigma) 10nM
reagents were added and the ethanol concentration in each
tube was adjusted to give a final working concentration of
0.2%. An 8 ml aliquot of 0.4% Noble agar in SFM at 56°C
was added and, after careful pipetting to mix, 1 ml aliquots
of the agar-cell mixture were dispensed into each of eight
replicate Falcon 2057 tubes (Falcon, UK), ensuring that no
agar was placed on the sides of the tubes and no air bubbles
were produced. The tubes were incubated at 37°C in a
humidifed atmosphere containing 5% carbon dioxide, 5%
oxygen and 90% nitrogen, with the caps of the tubes set in
the 'loose' position.
The cultures were 'fed' at weekly intervals with 1 ml ali-
quots of fresh SFM at 37C, containing appropriate endo-
crine reagents. Cultures of MCF-7 or Hs578T cells were
maintained for a period of 3 weeks and were thus 'fed' twice
during this time. Cultures of cells obtained directly from
pleural effusions were maintained for 4 weeks and were thus
'fed' on three occasions; on the third occasion 1 ml of
medium was removed from each culture tube prior to the
addition of fresh SFM.
At the end of the study period, 0.3 ml of prewarmed
iodonitrotetrazolium violet (Sigma) at 0.5 mg ml-' in double-
distilled water was added to each of the tubes, which were
placed in a 20% oxygen incubator for 24 h. The cultures
were fixed by adding 1-2 ml of 10% formol saline and
stored for short periods at 4°C prior to scoring colony forma-
tion. Viable colonies with diameters .60gim were identified
and counted using a Zeiss light microscope at x 400
magnification in conjunction with a semiautomated image
analysis system (Kontron Mopp-Videoplan). The colony-
forming efficiency (CFE) was calculated as the number of
colonies grown divided by the number ofviable breast cancer
cells plated and expressed as a percentage.
Experimental design
In each experiment, eight replicate cultures were set up for
each experimental condition. A standard plating density of
S x 0I cells per tube was employed in all experiments with
cell lines. In addition, further controls were set up containing
I0W cells per tube in order to establish the consistency of
control CFE in each experiment at different plating den-
sities.
Preliminary studies were performed with the aim of char-
acterising the growth of established human breast cancer cell
lines in the Courtenay-Mills assay under serum-free condi-
tions. The CFE of MCF-7 cells in serum-free conditions was
evaluated, and the endocrine sensitivity of the cells in the
assay was examined by assessing their responsiveness to oest-
radiol. The oestrogenic effects of phenol red on MCF-7
colony formation in the assay were also assessed.
Further studies evaluated the relative antioestrogenic
activity of40HT and ICI 182780 in MCF-7 cells. The poten-
tial for ICI 182780 to produce non-specific cytotoxic effects
was investigated in short-term exposure studies and oestrogen
reversibility experiments with MCF-7 cells. The ER depen-
dence of the activity of oestradiol and the two antioestrogens
in the Courtenay-Mills assay was investigated by evaluating
the effects of these agents in ER-negative Hs578T cells.206 D.J. DEFRIEND et al.
Finally, the relative oestrogenic activities of 40HT and ICI
182780 in the assay were studied by assessing their potential
to stimulate MCF-7 colony formation in the absence of other
exogenous oestrogens.
Experiments using primary cultures of cells from malignant
pleural effusions were used to investigate the effects of oest-
radiol and the two antioestrogens on cancer cells obtained
from patients with advanced breast cancer at the time of
disease relapse or progression on tamoxifen. The plating
density employed in each experiment varied according to the
yield of viable cancer cells obtained from the individual
effusions. As with the cell line studies, control cultures were
set up using at least two different plating densities in each
experiment. The effects of fixed concentrations of oestradiol
(0.1 nM) and 40HT/ICI 182780 (1OnM) were evaluated in
these studies. These concentrations were selected in order to
approximate the physiological/therapeutic, serum hormone/
drug levels typically observed in post-menopausal breast
cancer patients.
Statistical analysis
The results for each set of eight replicate cultures were
compared using non-parametric statistics. Differences in CFE
between experimental conditions were analysed using the
Mann-Whitney U-test for comparison of two specified con-
ditions and the Kruskal-Wallis test for comparisons of three
or more specified conditions. All statistical analyses were
performed on an Apple Macintosh personal computer, using
the StatView SE software program (Abacus Concepts,
Berkeley, CA, USA). The null hypothesis was rejected at a
probability level (P) of <0.05.
Results
Growth ofMCF-7 cells in the Courtenay-Mills assay
Initial experiments demonstrated that MCF-7 cells would
grow successfully as colonies in the Courtenay-Mills assay
under serum-free condition. Evaluation of colony formation
at different plating densities demonstrated a linear relation-
ship between the number of cells plated and the number of
colonies formed for plating densities ranging between 103 and
I0W cells per tube. In 14 separate experiments, in which a
standard phenol red-containing control condition was
included, the median CFE of the MCF-7 cells ranged
between 0.284% and 0.667%. The mean intra-assay co-
efficient of variation (CV) was 20.2%, and the inter-assay CV
was 23.8%.
Hormone responsiveness ofMCF-7 colonyformation
The sensitivity of MCF-7 colony formation to oestradiol was
examined by investigating the effects of a range ofconcentra-
tions of oestradiol on the CFE of cells cultured in defined
serum- and phenol red-free medium (SFMmF) (Figure 1). In
addition, the oestrogenic activity of phenol red in the assay
was investigated by measuring the CFE of cells grown in
separate control cultures using serum-free medium containing
phenol red (SFMpP). Oestradiol caused a significant and
dose-dependent increase in the CFE of MCF-7 cells at all
concentrations between 1 pM and 10 nM, and produced a
maximal stimulatory effect at a concentration of 1 nm. The
CFE of cells grown in SFMp was significantly greater than
that of cells grown in SFMptF. The stimulatory effect of
phenol red was found to be equivalent to that of adding
oestradiol at a concentration of between 1 and 10 pM.
Relative antioestrogenic effects ofICI 182780 and40HT
Initial studies using MCF-7 cells grown in SFMpR demon-
strated that 1 JLM concentrations of 40HT and ICI 182780
consistently inhibited the stimulatory effects of 1 nM oest-
radiol. Both antioestrogens reduced CFE to below the level
of phenol red-containing controls in these experiments, and a
tendency was noted for ICI 182780 to exhibit a greater
inhibitory effect on CFE than 40HT.
The relative antioestrogenic efficacy of ICI 182780 and
40HT was therefore examined in more detail using MCF-7
cells cultured in SFMmF. Escalating concentrations of the
antioestrogens were investigated in combination with a fixed
1 nM concentration of oestradiol (Figure 2). Both antioest-
rogens caused significant and dose-dependent inhibition of
oestrogen-stimulated colony formation at concentrations
between 10 nm and 1 FLM. However, at all concentrations
above 10 nM, ICI 182780 produced significantly greater
inhibition ofcolony formation than 40HT, and at concentra-
tions between 0.1 and 1.0JLM ICI 182780 reduced the CFE of
the MCF-7 cells to that of controls cultured in SFMNLF
alone. At the maximal inhibitory concentration of 1 gAM,
40HT reduced oestrogen-stimulated colony formation by
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Fige 2 Relative antioestrogenic effects of 4-hydroxytamoxifen
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17p-oestradiol. Points show median values; error bars indicate
interquartile ranges. Horizontal bands show the CFE of controls
([I ) grown in SFMpJ alone and of cells grown in medium
containing I nM oestradiol ( 1B ) for comparison. P<0.001
compared with I nm oestradiol alone; Mann-Whitney U-test.
P<0.001 compared with 4-hydroxytamoxifen; Mann-Whitney
U-test.
-1
I 1o
z
pIN VITRO PURE ANTIOESTROGEN W
approximately 90%, while ICI 182780 produced 100%
inhibition, resulting in a 5-fold difference in the CFE of
40HT- and ICI 182780-treated cultures (P<0.01,
Mann-Whitney U-test).
Cytotoxicity studies
ConventionaL non-steroidal antioestrogens including 40HT
have been shown to produce non-specific cytotoxic effects in
cultured breast cancer cells at concentrations exceeding 5 FM.
The potential of ICI 182780 to exhibit cytotoxic activity, at
the maximal antiproliferative concentration of 1 gAM used in
these studies, was examined in two ways.
Firstly, the acute effects of short-term exposure of MCF-7
cells to 1 JAM concentrations of 40HT or ICI 182780 were
investigated. MCF-7 cells growing in monolayer culture were
exposed to the antioestrogens or to the ethanol vehicle alone
for 1 h prior to washing and platng out in the Courtenay-
Mills assay without further antioestrogen exposure. Neither
of the antioestrogens exhibited significant effects on colony
formation in these studies (Figure 3), suggesting that no
acute cytotoxicity occurred at the drug concentrations
used.
Secondly, the reversibility of the antiproliferative activity
of ICI 182780 in MCF-7 cells was examined by increasng
the competing concentration of oestradiol. The inhibitory
effects of 1 FAM ICI 182780 were found to be fully reversible
by oestradiol, although only at concentrations exceeding
0.1IIM (Figure 4).
Colonyformation by ER-negative Hs578T cells
The ER dependence of the effects of oestradiol, 40HT and
ICI 182780 on cell growth in the Courtenay-Mills assay was
investigated using the ER-negative Hs578T human breast
cancer cell line.
The median CFE of Hs578T cells grown in SFMp under
control conditions was 1.58%, and was thus considerably
higher than that ofMCF-7 cells cultured under similar condi-
tions. The addition of oestradiol either alone or in combina-
tion with the two antioestrogens produced no significant
changes in the CFE of Hs578T cells (Figure 5).
Agonist effects of40HTand ICI 182780
The relative oestrogenic effects of 40HT and ICI 182780 in
the Courtenay-Mills assay were evaluated using MCF-7 cells
grown in SFMmF. The results of culturing the cells in the
presence of escalating concentrations of the antioestrogens
are illustrated in Figure 6.
40HT produced a biphasic effect on the CFE of MCF-7
cels, resulting in significant stimulation of colony formation
at concentrations between 10 pM and 10 nM, but significant
inhibition at concentrations between 0.1 and 1.0I1M com-
pared with control cultures. In contrast, ICI 182780 pro-
duced no stimulation of colony formation at any of the drug
concentrations studied. It did, however, cause significant
inhibition of colony formation at concentrations between
10 nM and 1 IJM compared with control cultures.
Prinary cultures ofcellsfrompleural effusions
Between January 1992 and April 1993 eight patients were
seen in the South Manchester Breast Unit who had relapsed
on tamoxifen therapy with metastatic pleural effusions. The
characteristics of these patients are summarised in Table
H.
The yield of viable cancer cells from the eight pleural
effusions ranged from 1.1 x 106 to 8.0 x 1O6 cells per effusion,
with a median yield of 3.85 x 106 cells.
Successful colony formation was obtained in primary cul-
tures of cells from six out of the eight effusions. The median
CFE of cells grown in SFMpF under control conditions
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Fiwe 3 Acute cytotoxicity of 4-hydroxytamoxifen (40HT) and
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Fuwe 5 Effects of 17p-oestradiol, 4-hydroxytamoxifen (40HT)
and ICI 182780 on colony formation by ER-negative Hs578T
breast cancer cells grown in SFM,. Columns show interquartile
ranges; bars indicate median values. P>0.5; Kruskal-Wallis
test.
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varied greatly between individual effusions, ranging from
0.023% to 0.66%.
The effects of oestradiol and the two antioestrogens on the
CFE of cells from these six effusions are summarised in
Figure 7. The results shown in this figure have been standar-
dised by expressing the CFE obtained for each experimental
condition as a percentage of the control CFE of the appro-
priate effusion. However, all statistical comparisons shown
were performed using the original absolute values.
The cells from two effusions, PE 5 and PE 7, appeared to
be generally endocrine resistant, such that the addition of
oestradiol and the two antioestrogens had no significant
effects on the CFE of these cells (P>0.1 and P>0.9 for
PE 5 and PE 7 respectively; Kruskal-Wallis test).
The cells from the remaining four effusions exhibited
evidence of continued endocrine responsiveness, as shown by
-6 the significant stimulatory effects of oestradiol in these cul-
tures. 40HT produced significant inhibition of the basal CFE
level in two effusions (PE 1 and PE 2), but caused significant
inhibition of oestrogen-stimulated colony formation in only
one of these cases (PE 1). ICI 182780 produced significant
inhibition of the basal CFE level in three effusions, and
caused significant inhibition of oestrogen-stimulated colony
formation in all four cases.
40HT produced significant stimulation of CFE in two
primary cultures, PE4 and PE8. ICI 182780 exhibited no
stimulatory activity in any of the primary cultures and
caused significant inhibition of 40HT-stimulated colony for-
mation in cases PE4 and PE 8.
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Fngwe 7 Responses of cancer cells from six clonogenic pleural effusions to oestradiol (E2), 4-hydroxytamoxifen (4OHT) and ICI
182780. Columns show CFEs as percentages of the control CFE for each effusion. P<0.01 compared with controls;
Mann-Whitney U-test. **P <0.01 compared with E2 alone; Mann-Whitney U-test. #P <0.01 compared with 40HT alone;
Mann-Whitney U-test. El, 0.1 nM E2; -, 10 nM 40HT; - , 0 nM ICI 182780; - , E2 + 40HT; -, E2 + ICI 182780;
EJ, 40HT + ICI 182780.
Tablk Characteristics of the eight patients who relapsed on tamoxifen with malignant pleural effusions due to metastatic
breast cancer
Primary tumour Tanoxifen Rx
Patient Age Menopausal ER PR Duration
ID (years) status Histology status status (months) Response
PE 1 67 Post IDC Positive Negtive 6 NC
PE 2 61 Post IDC Positive Neptive 6 PD
PE 3 74 Post ILC Positive Positive 8 NC
PE 4 63 Post IDC Positive Negative 24 NC
PE 5 37 Pre IDC Negative Negtive 12 Adjuvant Rx
PE 6 41 Pre IDC Negative Negtive 14 Adjuvant Rx
PE 7 66 Post ILC Negtive Negative 24 NE
PE 8 68 Post IDC Positive Negtive 21 Adjuvant Rx
IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma; NC, no change; PD, progressive disease; NE, not
evaluable; Rx, treatment.
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Soft-agar clonogenic assays provide a means of culturing
cancer cells obtained directly from human malignancies with-
out the overgrowth of normal cells (Hamburger & Salmon,
1977; Courtenay & Mills, 1978). They have previously been
used in the field of breast cancer research principally to study
the intrinsic sensitivity of tumours to cytotoxic agents (Ditt-
rich et al., 1985; Jones et al., 1985; Staquet et al., 1987; Von
Hoff et al., 1983) or to investigate the prognostic significance
of tumour clonogenicity (Smallwood et al., 1984; Dittrich et
al., 1985; Nomura et al., 1989; Ottestad et al., 1989). A small
number of studies, however, have used clonogenic assays to
investigate the endocrine sensitivity of established breast
cancer cell lines (Goldenberg & Froese, 1982; Kodama et al.,
1985; Osborne etal., 1985; Manni etal., 1991) orcancer cells
obtained directly from primary or metastatic human breast
tumours (Manni et al., 1985; Osborne et al., 1985; Nomura et
al., 1990).
The majority of these studies were conducted using the
Hamburger-Salmon human tumour-cloning assay (Ham-
burger & Salmon, 1977). However, the Courtenay-Mills
clonogenic assay (Courtenay & Mills, 1978) was selected for
use in the present study because it has been shown previously
to yield superior CFEs in studies with breast tumours (Ottes-
tad et al., 1988) and other human malignancies (Tveit et al.,
1981).
The standard methodology of the Courtenay-Mills assay
includes the use of medium containing 15% FCS (Courtenay
& Mills, 1978). Unfortunately, the addition of serum to
growth media can introduce a number of uncontrolled
variables into in vitro assays which may mask the respon-
siveness of breast cancer cells to steroid hormones and hor-
mone antagonists. These variables include endogenous
steroid hormones and various soluble factors which appear
to regulate their activity (Darbre et al., 1983; Devleeschouwer
et al., 1987). In order to optimise the Courtenay-Mills assay
for the evaluation of breast cancer cell sensitivity to endo-
crine agents, the assay method was modified in the present
study by the use of defined SFM. The SFM used was based
on a formulation previously shown by Wilis and West (1991)
to support the growth of human cervical cancer cells in the
Courtenay-Mills assay.
Successful clonogenic growth of breast cancer cells in SFM
has only been reported previously by Manni et al. (1985,
1991) using the Hamburger-Salmon assay. The present study
thus represents the first demonstration of successful growth
of breast cancer cells in the Courtenay-Mills clonogenic
assay under serum-free conditions.
Preliminary experinents with MCF-7 cells showed that
their CFE is linear over a range of plating densities and
demonstrated acceptable levels of intra- and inter-assay
variability. In addition, these experiments confirmed that the
growth of the MCF-7 cells in the Courtenay-Mills assay is
hormone responsive, as shown by the dose-dependent
stimulation of CFE by oestradiol. Although the oestrogen
sensitivity of MCF-7 cells in monolayer culture has been well
established since first reported by Lippman et al. (1976),
there appears to have been no previous reports of the effects
of oestrogen on breast cancer cells cultured using the
Courtenay-Mills clonogenic assay. In a previous study using
the Hamburger-Salmon assay, Manni et al. (1991) demon-
strated stimulatory effects of oestradiol in MCF-7 cells cul-
tured in SFM similar to those seen in the present study.
The oestrogen sensitivity of the MCF-7 cells was demon-
strable in the present study despite the presence in the growth
medium of a number of supplements that have been shown
to improve the clonogenicity of human tumours and which
might therefore have potentially masked the stimulatory
effects of oestradiol. These include epidermal growth factor
(Pathak et al., 1982), hydrocortisone and insulin (Hug et al.,
1984; Kern et al., 1984) and transferrin (Calvo et al., 1983).
Investigation of the effects of phenol red in the present study
showed that it exhibited weak oestrogenic effects on the CFE
of MCF-7 cells in the Courtenay-Mills assay. This finding is
in accordance with a number of previous studies that have
demonstrated oestrogen-like stimulation by phenol red of
breast cancer cells grown in monolayer culture (Berthois et
al., 1986; Welshons et al., 1988). These findings emphasise
the importance of excluding phenol red from the culture
conditions when undertaking in vitro studies to examine the
activity of other potential weak oestrogens such as tamoxi-
fen.
Investigation of the relative antioestrogenic activity of
40HT and ICI 182780 in the present study demonstrated
that ICI 182780 acted as a more potent oestrogen antagonist
at concentrations exceeding 10nM. This result was demon-
strable despite the fact that both 40HT and ICI 182780 have
similar binding affinities for the ER (Wakeling et al., 1991)
and is in accordance with the findings of previous in vitro
studies with pure antioestrogens (Wakeling et al., 1991;
Favoni et al., 1993).
The results of preliminary experiments in which SFMpR
was used showed that, at 1 FM concentrations, both 40HT
and ICI 182780 reduced the CFE of MCF-7 cells to signifi-
cantly below the level of untreated controls. These effects
were considered to have most likely resulted from elevation
of the CFE of controls by the oestrogenic activity of phenol
red. However, in some of the subsequent experiments that
were performed using SFMmF, high (0.1-1.0gM) concentra-
tions of ICI 182780 continued to reduce the CFE of MCF-7
cells to below the level of controls from which all exogenous
oestrogens, including phenol red, had been excluded.
These findings may be explained in three ways. Firstly,
they may simply demonstrate antagonism by ICI 182780 of
retained intracellular steroids carried over by the MCF-7 cells
during transfer from stock monolayer culture in SCM into
the Courtenay-Mills assay. Previous studies have shown that
breast cancer cells can retain intracellular steroids for pro-
longed periods following transfer from oestrogen-containing
to oestrogen-free growth conditions (Strobl & Lippman,
1979). The potential confounding effects of this so-called
'steroid memory' might have been avoided in the present
study by maintenance of the stock monolayer cultures of
MCF-7 cells in SFMmF. However, this might potentially
have selected out hormone-independent MCF-7 cell clones.
Secondly, the findings may have resulted from antagonism
by ICI 182780 of other potential mitogens, including insulin
and EGF, contained in the SFM formulation used in the
present study to culture cells in the Courtenay-Mills assay.
Conventional antioestrogens including tamoxifen have been
reported to antagonise the mitogenic effects of peptide
growth factors including insulin-like growth factor type 1
(IGF-1) and epidermal growth factor (EGF) in the absence
of oestrogens (Vignon et al., 1987; Wosikowski et al.,
1993).
Finally, the findings may have been due to cytotoxic
activity occurring at high concentrations of ICI 182780. Non-
steroidal antioestrogens, including 40HT, have previously
been shown to cause specific ER-mediated cytotoxic effects at
concentrations between 10 nM and 1 FuM (Bardon et al., 1987)
and non-specific ER-independent cytotoxic effects at concen-
trations exceeding 5gM (Green et al., 1981; Lippman et al.,
1981). The lack of activity of ICI 182780 in ER-negative
Hs578T cells seen in the present study suggests that the
antiproliferative effects of this agent in MCF-7 cells were ER
dependent and were not due to non-specific cytotoxicity.
Furthermore, the reversibility of the effects of ICI 182780 in
MCF-7 cells by oestradiol and the lack of acute cytotoxic
effects seen during short-term antioestrogen administration to
MCF-7 cells suggest that ICI 182780 did not cause significant
levels of spcific, ER-dependent cytotoxicity in the present
study.
Evaluation of the relative agonist effects of40HT and ICI
182780 on the CFE of MCF-7 cells cultured in SFMpRF
demonstrated that 40HT but not ICI 182780 caused signifi-
cant stimulation ofcolony formation at low (10pM to 10 nM)
concentrations. These findings are in accordance with
previous studies using monolayer culture techniques that
have demonstrated growth stimulation of a number of hor-210 DJ. DEFRIEND et al.
mone-responsive breast cancer cell lines by low concentra-
tions of tamoxifen or 40HT (Roos et al., 1982; Darbre et al.,
1984; Reddel & Sutherland, 1984; Katzenellenbogen et al.,
1987; Thompson et al., 1989; Wakeling et al., 1989) but not
by the pure antioestrogens ICI 164384 or ICI 182780
(Thompson et al., 1989; Wakeling et al., 1991).
The experiments performed in the present study using
primary cultures of tumour cells from malignant pleural
effusions were designed to look for evidence of stimulation
by 40HT of the clonogenic growth of cells taken directly
from breast cancer patients who appeared to be tamoxifen
resistant. In addition, the experiments were designed to
evaluate the sensitivity of tumour cells from tamoxifen-
resistant patients to oestradiol and ICI 182780.
One disadvantage associated with the use of pleural
effusions as sources of breast cancer cells in the present study
was the relatively small number of suitable patients seen in
the breast clinic with malignant effusions during the 14
month study period. Consequently, primary culture of meta-
static cancer cells using the Courtenay-Mills assay could
only be attempted in eight cases.
Of the eight pleural effusions cultured, six yielded tumour
cells that successfully formed colonies in the Courtenay-
Mills assay under serum- and phenol red-free culture condi-
tions. The CFEs of the primary cultures under control condi-
tions were highly variable, but were within the range ofCFEs
previously reported by Ottestad et al. (1988) for 237 primary
or recurrent breast tumours cultured in the Courtenay-Mills
assay using SCM.
The different responses to oestradiol and the two antioest-
rogens seen in the six successful primary cultures provide
preliminary evidence to suggest that breast cancer cells from
tamoxifen-resistant patients exhibit at least three patterns of
in vitro hormone-responsiveness: (i) generalised hormone
independence; (ii) continued sensitivity to oestradiol and to
the antioestrogenic activity of ICI 182780 but overall resis-
tance to 4OHT; and (iii) stimulation by oestradiol and 40HT
and inhibition of both oestradiol- and 40HT-stimulated
growth by ICI 182780. Although the results of these primary
culture experiments must be viewed as preliminary because of
the small patient numbers involved, it is noteworthy that
four previous studies have found evidence of stimulation by
tamoxifen of breast cancer cells cultured directly from
patients (Simon et al., 1984b; Manni et al., 1985; Osborne et
al., 1985; Nomura et al., 1990).
It is concluded from this study that the Courtenay-Mills
soft-agar clonogenic assay is suitable for investigating the
effects of endocrine agents on the growth of established
breast cancer cell lines and metastatic breast cancer cells
taken directly from patients. At drug concentrations exceed-
ing 10 nM, the novel steroidal antioestrogen, ICI 182780,
exhibits a more complete and potent antioestrogenic effect
than 40HT on colony formation by hormone-responsive
breast cancer cells and, unlike 40HT, ICI 182780 exhibits no
demonstrable agonist activity. Investigation of the effects of
these agents in metastatic breast cancer cells taken from
patients at the time of relapse on tamoxifen provides pre-
liminary evidence to suggest that some patients may fail on
tamoxifen therapy because of the oestrogenic activity of the
parent drug and/or its metabolites and that treatment with a
pure antioestrogen may be effective in patients with advanced
breast cancer who appear to be resistant to tamoxifen.
A*bbiadow ER, oestrogen receptor, CFE, colony-forming
efficncy; SCM, serum-containing growth medium; SFMpR, serum-
free growth medium containing phenol red; SFMmF, serwm-free/
phenol red-free growth medium; 40HT, 4-hydroxytamoxifen; ICI
182780, 7{-[9-(4,4,5,5,5-pentafluoropentylsulhpinyl)nonyloestra-1,3,5,
(I0)triene-3, 17B diol.
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